Logo image of SCNX

SCIENTURE HOLDINGS INC (SCNX) Stock Fundamental Analysis

NASDAQ:SCNX - US80880X1046 - Common Stock

1.02 USD
-0.01 (-0.97%)
Last: 8/28/2025, 8:00:02 PM
1.02 USD
0 (0%)
After Hours: 8/28/2025, 8:00:02 PM
Fundamental Rating

1

Overall SCNX gets a fundamental rating of 1 out of 10. We evaluated SCNX against 35 industry peers in the Health Care Technology industry. SCNX may be in some trouble as it scores bad on both profitability and health. SCNX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCNX has reported negative net income.
In the past year SCNX has reported a negative cash flow from operations.
In the past 5 years SCNX reported 4 times negative net income.
In the past 5 years SCNX always reported negative operating cash flow.
SCNX Yearly Net Income VS EBIT VS OCF VS FCFSCNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -14.33%, SCNX perfoms like the industry average, outperforming 51.43% of the companies in the same industry.
SCNX has a Return On Equity (-18.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -14.33%
ROE -18.78%
ROIC N/A
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
SCNX Yearly ROA, ROE, ROICSCNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

SCNX's Gross Margin of 4.56% is on the low side compared to the rest of the industry. SCNX is outperformed by 82.86% of its industry peers.
In the last couple of years the Gross Margin of SCNX has declined.
SCNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
SCNX Yearly Profit, Operating, Gross MarginsSCNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K -10K

More info and screens

3

2. Health

2.1 Basic Checks

SCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCNX has been increased compared to 1 year ago.
The number of shares outstanding for SCNX has been increased compared to 5 years ago.
SCNX has a better debt/assets ratio than last year.
SCNX Yearly Shares OutstandingSCNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
SCNX Yearly Total Debt VS Total AssetsSCNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -0.55, we must say that SCNX is in the distress zone and has some risk of bankruptcy.
SCNX's Altman-Z score of -0.55 is in line compared to the rest of the industry. SCNX outperforms 42.86% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that SCNX is not too dependend on debt financing.
SCNX has a Debt to Equity ratio of 0.02. This is in the better half of the industry: SCNX outperforms 62.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -0.55
ROIC/WACCN/A
WACC9.62%
SCNX Yearly LT Debt VS Equity VS FCFSCNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.05 indicates that SCNX should not have too much problems paying its short term obligations.
SCNX has a worse Current ratio (1.05) than 71.43% of its industry peers.
A Quick Ratio of 1.05 indicates that SCNX should not have too much problems paying its short term obligations.
The Quick ratio of SCNX (1.05) is worse than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 1.05
SCNX Yearly Current Assets VS Current LiabilitesSCNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.04% over the past year.
The Revenue for SCNX has decreased by -97.79% in the past year. This is quite bad
SCNX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -55.05% yearly.
EPS 1Y (TTM)5.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.01%
Revenue 1Y (TTM)-97.79%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNX Yearly Revenue VS EstimatesSCNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
SCNX Yearly EPS VS EstimatesSCNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCNX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCNX Price Earnings VS Forward Price EarningsSCNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNX Per share dataSCNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SCNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCIENTURE HOLDINGS INC

NASDAQ:SCNX (8/28/2025, 8:00:02 PM)

After market: 1.02 0 (0%)

1.02

-0.01 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-07 2025-08-07
Earnings (Next)11-04 2025-11-04
Inst Owners1.27%
Inst Owner Change-3.56%
Ins Owners17.82%
Ins Owner ChangeN/A
Market Cap16.45M
Analysts82.86
Price TargetN/A
Short Float %0.49%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend3.08
Dividend Growth(5Y)N/A
DP-14.35%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 111.92
P/FCF N/A
P/OCF N/A
P/B 0.2
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.7
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.01
BVpS5.03
TBVpS-1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.33%
ROE -18.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.56%
FCFM N/A
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 1.05
Altman-Z -0.55
F-Score1
WACC9.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.01%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-97.79%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-252.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-381.64%
OCF growth 3YN/A
OCF growth 5YN/A